Join the Oncology Voice Network. Join for Free
Towards a novel approach guiding the decision-making process for anticancer treatment in patients with advanced cancer: framework for systemic anticancer treatment with palliative intent
Patient-centered cancer care Advanced cancer decision-making Stepwise decisional process Palliative care domains Illness understanding in oncology Symptom control in cancer End-of-life preparation Patient-physician interaction SACT-PI Decision Fra

Towards a novel approach guiding the decision-making process for anticancer treatment in patients with advanced cancer: framework for systemic anticancer treatment with palliative intent


Share This Article


Summary

  • Patient-centered decisions in advanced cancer care demand a step-wise decisional process, not a single decision act.

  • The decision process includes key palliative care domains, e.g. illness understanding, symptom control, or end-of-life preparation.

  • Patients' attitudes, beliefs, hopes, patient-physician interaction, and physician attitudes demand structured observation.

  • The SACT-PI Decision Framework includes concrete steps: assess, educate, verify, reflect, discuss, weigh, pause, decide.

  • Inter-professionally working oncology clinicians may transform decision-making processes in oncology beyond decision aids. 

Oncologists typically base treatment recommendations on survival, tumor control, and toxicity data from high-quality clinical trials.¹ In patients with resistant tumors and in unfit patients, anticancer treatment is often applied even without sufficient supporting evidence. Many patients may face toxicity with modest benefit from such treatments,² whereas, in others, a systemic anticancer treatment with palliative intent (SACT-PI) may alleviate cancer-related symptoms.³,⁴

In modern oncology, patients with advanced disease often face uncertainty⁵ and may have inaccurate perceptions of their prognosis⁶,⁷ and treatment goals.⁸ Moreover, they may have difficulties weighing the toxicity risk against potential benefits in terms of symptom control and quality of life.⁹ These factors can compromise informed decision-making and may contribute to so-called aggressive end-of-life care.¹⁰ An individualized decision process¹¹ becomes increasingly important to address palliative care (PC) domains like multidimensional symptom burden, illness and prognosis understanding,¹² spirituality,¹³ life closure,¹⁴ or family involvement.¹⁵

Current evidence suggests that non-medical factors like attitudes, values and beliefs, sociodemographic variables such as (young) age, and aspects of the physician-patient relationship may influence SACT decisions.¹⁶ Current evidence to guide oncologists’ decision-making for or against SACT-PI is rare.

Click for Source Download PDF version
Patient-centered cancer care, Advanced cancer decision-making, Stepwise decisional process, Palliative care domains, Illness understanding in oncology, Symptom control in cancer, End-of-life preparation, Patient-physician interaction, SACT-PI Decision Fra

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Explore OVN